Codiak BioSciences, Inc.

Sana Biotechnology is curbing its ambitions and cutting costs for a second time in less than a year in response to shrinking cash reserves and diminishing investor confidence. It will cut headcount b

Mariana Oncology Inc. CEO Simon Read believes that one of the reasons his company was able to raise the $175m series B venture capital round announced on 7 September was its differentiated approach t

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Talaris Calls It Quits In Reverse-Merge

With investors closely watching how biopharmaceutical companies are spending the cash they have on hand so that they do not run out of money in a tough fundraising environment, even firms with revenue